IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Chiricozzi, Andrea ^a,b   Nograles, Kristine E ^a   Johnson Huang, Leanne M ^a   Fuentes Duculan, Judilyn ^a   Cardinale, Irma ^a   Bonifacio, Kathleen M ^a   Gulati, Nicholas ^a   Mitsui, Hiroshi ^a   Guttman Yassky, Emma ^a,c   Suarez Farinas, Mayte ^a   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 2; CCAAT ENHANCER BINDING PROTEIN BETA; INTERLEUKIN 17; IXEKIZUMAB; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ARTICLE; BIOLOGICAL MODEL; C EBP BETA GENE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RESPONSIVE ELEMENT; DOWN REGULATION; EPIDERMIS; GAMMA DELTA T LYMPHOCYTE; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INDUCTION; GENE PROBE; GENE REPRESSION; GENETIC ASSOCIATION; HBD2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; LCN2 GENE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS VULGARIS; T LYMPHOCYTE; TC17 CELL; TH17 CELL; TRANSCRIPTION REGULATION; UPREGULATION;

BETA-DEFENSINS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; EPIDERMIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-17; KERATINOCYTES; LIPOCALINS; TISSUE CULTURE TECHNIQUES; TISSUE ENGINEERING;

EID: 84896503749     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090284     Document Type: Article

References (56)

1. Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG (2013) The IL-23/ T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 34: 174-81.
2. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, et al. (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-32. (Pubitemid 41541790)
3. Park H, Li Z, Yang XO, Chang SH, Nurieva R, et al. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-41. (Pubitemid 41541791)
4. Cai Y, Shen X, Ding C, Qi C, Li K, et al. (2011) Pivotal role of dermal IL-17-producing gamma/delta T cells in skin inflammation. Immunity 35: 596-610.
5. Ortega C, Fernandez AS, Carrillo JM, Romero P, Molina IJ, et al. (2009) IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukocyte Biol 86: 435-43.
6. Lin AM, Rubin CJ, Khandpur R, Wang JY, Riblett M, et al. (2011) Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 187: 490-500.
7. Gaffen SL (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9: 556-67.
8. Ruddy MJ, Wong GC, Liu XK, Yamamoto H, Kasayama S, et al. (2004) Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem 279:2559-67. (Pubitemid 38114241)
9. Albanesi C, Cavani A, Girolomoni G (1999) IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 162: 494-502. (Pubitemid 29018959)
10. Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles KE, Tian S, et al. (2011) Integrative Responses to IL-17 and TNF-alpha in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis. J Invest Dermatol 131: 677-87.
11. Laan M, Lotvall J, Chung KF, Linden A (2001) IL-17-induced cytokine release in human bronchial epithelial cells in vitro: role of mitogen-activated protein (MAP) kinases. Br J Pharmacol 133: 200-6. (Pubitemid 32500468)
12. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suarez-Farinas M, et al. (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159: 1092-102.
13. Pickens SR, Volin MV, Mandelin AM 2nd, Kolls JK, Pope RM, et al. (2010) IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol 184: 3233-41.
14. Roussel L, Houle F, Chan C, Yao Y, Berube J, et al. (2010) IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 184: 4531-7.
15. Ruddy MJ, Shen F, Smith JB, Sharma A, Gaffen SL (2004) Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment. J Leukocyte Biol 76: 135-44. (Pubitemid 38857180)
16. Shen F, Ruddy MJ, Plamondon P, Gaffen SL (2005) Cytokines link osteoblasts and inflammation: microarray analysis of interleukin-17- and TNF-alphainduced genes in bone cells. J Leukocyte Biol 77: 388-99. (Pubitemid 40289569)
17. Arican O, Aral M, Sasmaz S, Ciragil P (2005) Serum levels of TNF-alpha, IFNgamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005:273-9. (Pubitemid 41577417)
18. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, et al. (2004) Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris. J Exp Med 199:125-30. (Pubitemid 38076484)
19. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, et al. (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128: 1207-11. (Pubitemid 351543220)
20. Zaba L, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, et al. (2007) Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204: 3183-94.
21. Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, et al (2009) Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 29:210-4.
22. Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, et al. (2007) Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 122: 201-6. (Pubitemid 47241785)
23. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, et al. (2007) A largescale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80: 273-90. (Pubitemid 46175676)
24. Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, et al. (2008) Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 128: 1653-61. (Pubitemid 351847381)
25. Johnson-Huang LM, Suarez-Farinas M, Sullivan-Whalen M, Gilleaudeau P, Krueger JG, et al (2010) Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol 130: 2654-63.
26. Piskin G, Tursen U, Sylva-Steenland RM, Bos JD, Teunissen MB (2004) Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers - IL-12, IL-18 and IL-23. Exp Dermatol 13: 764-72. (Pubitemid 39625223)
27. Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, et al. (2009) Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 124: 1022-10.
28. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, et al. (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2: 52ra72.
29. Krueger JG, Fretzin S, Suarez-Farinas M, Haslett PA, Phipps KM, et al. (2012) IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 130: 145-54.
30. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, et al. (2012) Antiinterleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366: 1190-9.
31. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-74. (Pubitemid 351671883)
32. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet 371: 1675-84. (Pubitemid 351671884)
33. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, et al. (2012) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366:1181-9.
34. Scheynius A, Fransson J, Johansson C, Hammar H, Baker B, et al. (1992) Expression of interferon-gamma receptors in normal and psoriatic skin. J Invest Dermatol 98: 255-8.
35. Trefzer U, Brockhaus M, Loetscher H, Parlow F, Kapp A, et al. (1991) 55-kd tumor necrosis factor receptor is expressed by human keratinocytes and plays a pivotal role in regulation of human keratinocyte ICAM-1 expression. J Invest Dermatol 97: 911-6.
36. Gulati N, Krueger JG, Suárez-Fariñas M, Mitsui H (2013) Creation of Differentiation-Specific Genomic Maps of Human Epidermis Through Laser Capture Microdissection. J Invest Dermatol. 133: 2640-2.
37. Morizane S, Gallo RL (2012) Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol 39: 225-30.
38. Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D, et al. (2007) Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med 204: 2603-14. (Pubitemid 350044786)
39. Trepicchio WL, Ozawa M, Walters IB, Kikuchi T, Gilleaudeau P, et al. (1999) Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104: 1527-37. (Pubitemid 30002364)
40. Tian S, Krueger JG, Li K, Jabbari A, Brodmerkel C, et al. (2012) Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease. PloS One 7: e44274.
41. Suarez-Farinas M, Fuentes-Duculan J, Lowes MA, Krueger JG (2011) Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol 131: 391-400.
42. Nograles KE, Suarez-Farinas M, Shemer A, Fuentes-Duculan J, Chiricozzi A, et al. (2010) Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses.J Allergy Clin Immunol 125: 744-6, 6 e1-6 e2.
43. Johnston A, Xing X, Guzman AM, Riblett M, Loyd CM, et al. (2011) IL-1F5, -F6, -F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol 186: 2613-22.
44. Rizzo HL, Kagami S, Phillips KG, Kurtz SE, Jacques SL, et al. (2011) IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 186: 1495-502.
45. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, et al. (2007) The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178: 2229-40. (Pubitemid 46233421)
46. Muhr P, Zeitvogel J, Heitland I, Werfel T, Wittmann M (2011) Expression of interleukin (IL)-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors. Br J Dermatol 165: 189-93.
47. Tohyama M, Hanakawa Y, Shirakata Y, Dai X, Yang L, et al. (2009) IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol 39: 2779-88.
48. Ganguly D, Chamilos G, Lande R, Gregorio J, Meller S, et al. (2009) Self-RNAantimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 206: 1983-94.
49. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, et al. (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449: 564-9. (Pubitemid 47525141)
50. Suárez-Fariñas M, Dhingra N, Gittler J, Shemer A, Cardinale I, et al. (2013) Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 132: 361-70.
51. Zaba LC, Fuentes-Duculan J, Steinman RM, Krueger JG, Lowes MA (2007) Normal human dermis contains distinct populations of CD11cBDCA-1 dendritic cells and CD163FXIIIA macrophages. J Clin Invest 117: 2517-2525. (Pubitemid 47494353)
52. Zhou X, Krueger JG, Kao MC, Lee E, Du F, et al. (2003) Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 13: 69-78. (Pubitemid 37129170)
53. Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, et al. (2005) Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A. 102: 2075-80. (Pubitemid 40262014)
54. Suárez-Fariñas M, Pellegrino M, Wittkowski KM, Magnasco MO (2005) Harshlight: a "corrective make-up" program for microarray chips. BMC Bioinformatics 6: 294.
55. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F. (2004) A Model-Based Background Adjustment for Oligonucleotide Expression Arrays. J Am Stat Assoc 99: 909-917. (Pubitemid 39665934)
56. Suarez-Farinas M, Lowes MA, Zaba LC, Krueger JG (2010) Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). PLoS One 5:e10247.